ArticleAbdominal radiology (New York)2026
Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo evaluate the value of dual-layer spectral detector CT (DLCT) for predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma (PDAC). MATERIALS &
methodsThis retrospective study included untreated patients with pathologically confirmed PDAC who underwent DLCT between June 2019 and September 2023. Independent relevant clinical-radiological features and quantitative parameters for predicting Ki-67 proliferation status and p53 mutations were identified using multivariate logistic regression analysis. The diagnostic performances of independent variables were evaluated using receiver operating characteristic curves.
resultsWe included 92 patients (60.19 ± 11.22 years old, 61 males). There were 40 patients with high Ki-67 expression (Ki-67 ≥ 25%) and 43 patients positive for p53 mutation. The radiologists showed substantial or near-perfect inter- and intra-observer agreement in evaluating quantitative parameters. Normalised iodine concentration in the arterial phase (nICa) was the only independent predictor of Ki-67 proliferation status (p < 0.001; adjusted odds ratio [OR], 2.33; 95% confidence interval [CI]: 1.46, 3.74; cut-off, 0.0910) and p53 mutations (p < 0.001; adjusted OR, 1.35; 95% CI: 1.07, 1.71; cut-off, 0.0905) according to the multivariate logistic analysis. nICa showed satisfactory performance when using the chosen rounded cut-off value of 0.090 (easily applicable in clinical practice) in predicting Ki-67 proliferation (area under the receiver operating characteristic curve [AUC], 0.812; sensitivity, 87.5%; specificity, 75.0%) and p53 mutations (AUC, 0.731; sensitivity, 76.7%; specificity, 69.4%).
conclusionThe DLCT parameter nICa enables simultaneous and non-invasive prediction of both Ki-67 proliferation status and p53 mutations in PDAC with satisfactory diagnostic efficacy.
Indexed as
Identifiers
40658136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.